Eleven Biotherapeutics appoints Richard F. Fitzgerald as interim CFO
Mr. Fitzgerald brings over two decades of financial and strategic leadership to Eleven Biotherapeutics.
Most recently, he served as a consultant to private life science based companies from July 2017 through October 2017.
Before that, Mr. Fitzgerald served as Chief Financial officer of Pavmed Inc., where he completed its IPO in April 2016.
He previously served as Chief Financial Officer at Techprecision Corporation and Nucleonics Inc., and in several financial and business development positions of increasing responsibility at Exelon Corporation.
Mr. Fitzgerald holds his B.S. in Business Administration from Bucknell University.